Blog

IN-ARMOR is a European research project funded by HADEA, whose main objective is to combat antimicrobial resistance, one of the greatest threats to global health today, an ambition shared with Vibiosphen.

Most bacteria live in the form of biofilms, that is, aggregated communities of microorganisms with a complex architecture, encapsulated within a network of hydrated polysaccharides and DNA. The formation of these biofilms confers substantial robustness to bacteria. Indeed, biofilm-associated infections are particularly problematic due to antimicrobial resistance.

Effective management of AMR and CC demands robust economic and political actions. Global and national plans should be aligned to address these interconnected challenges. Policies need to encourage the responsible use of antimicrobials and foster environmental sustainability. 

In the face of escalating antimicrobial resistance (AMR), researchers and innovators are turning to advanced technologies like Artificial Intelligence (AI) and genomic sequencing to pave new roads in the battle against superbugs.

In the wake of the upcoming UN General Assembly, the spotlight turns to a pressing global health challenge: antimicrobial resistance (AMR). 

The 6M € granted to IN-ARMOR project will optimize an already developed drug platform using Computer Aided Drug Design. 

By zooming in the mechanism that bacteria use to escape the antibiotics, we find three different subgroups – resistance – tolerance – persistence.

Distinguishing these three groups is key in the fight against bacterial infection.

Cystic fibrosis is an inherited disease that causes a buildup of thick mucus in the lungs, leading to repeated bacterial infections that damage the lungs and can cause respiratory failure.

Adding to this problem when the bacterial infection become resistant bacteria the treatment of the patient become really challenging.

On the one hand, antibiotics are one of the most powerful tools to save lives. The breakthrough that saved many lives also gets its dark side. Despite the decreasing efficacy in the treatment of patients and the rise of resistance due to the misuse of antibiotics and not of antibiotics themselves, scientists have found a real downside: the impact on the gut microbiota.

 “a growing number of studies are finding that even a short course of antibiotics can alter the makeup of the bacterial species in the gut.” 

Antimicrobial resistance (AMR) is often viewed as a concept but not as a reality. Highlighting stories of real-life dramatic patient AMR is essential for sensibilization. 

Nowadays, we face the Covid-19 pandemics but under our radar the silent pandemic is rising. It is common to hear about the outbreaks of flu, malaria, or outbreaks from new Covid-19 variant. It is less common to heard about the outbreaks of antimicrobial resistance (AMR) referred as the silent pandemic.

The emergence of bacterial pathogens with acquired resistance to almost all available antimicrobials is one of the major concerns today. Resistant pathogens are causing 700,000 deaths per year. It is expected by 2050 that infectious diseases will be responsible for more than 10 million deaths per year, a number higher than the 8.2 million caused by cancer today.